|Kelch-like 3 and Cullin 3 regulate electrolyte homeostasis via ubiquitination and degradation of WNK4|
S Shibata, J Zhang, J Puthumana, KL Stone, RP Lifton
Proceedings of the National Academy of Sciences 110 (19), 7838-7843, 2013
|Angiotensin II signaling via protein kinase C phosphorylates Kelch-like 3, preventing WNK4 degradation|
S Shibata, JP Arroyo, M Castañeda-Bueno, J Puthumana, J Zhang, ...
Proceedings of the National Academy of Sciences 111 (43), 15556-15561, 2014
|Biomarkers for the detection of renal fibrosis and prediction of renal outcomes: a systematic review|
SG Mansour, J Puthumana, SG Coca, M Gentry, CR Parikh
BMC nephrology 18 (1), 1-13, 2017
|YKL-40 associates with renal recovery in deceased donor kidney transplantation|
J Puthumana, IE Hall, PP Reese, B Schröppel, FL Weng, ...
Journal of the American Society of Nephrology 28 (2), 661-670, 2017
|Urine interleukin 18 and lipocalin 2 are biomarkers of acute tubular necrosis in patients with cirrhosis: a systematic review and meta-analysis|
J Puthumana, X Ariza, JM Belcher, I Graupera, P Ginès, CR Parikh
Clinical Gastroenterology and Hepatology 15 (7), 1003-1013. e3, 2017
|Relationship of kidney injury biomarkers with long-term cardiovascular outcomes after cardiac surgery|
CR Parikh, J Puthumana, MG Shlipak, JL Koyner, H Thiessen-Philbrook, ...
Journal of the American Society of Nephrology 28 (12), 3699-3707, 2017
|Clinical trial evidence supporting FDA approval of drugs granted breakthrough therapy designation|
J Puthumana, JD Wallach, JS Ross
Jama 320 (3), 301-303, 2018
|Phosphorylation by PKC and PKA regulate the kinase activity and downstream signaling of WNK4|
M Castañeda-Bueno, JP Arroyo, J Zhang, J Puthumana, O Yarborough, ...
Proceedings of the National Academy of Sciences 114 (5), E879-E886, 2017
|Availability of investigational medicines through the US Food and Drug Administration’s expanded access and compassionate use programs|
J Puthumana, JE Miller, J Kim, JS Ross
JAMA network open 1 (2), e180283-e180283, 2018
|Assessment of clinical trials supporting US Food and Drug Administration approval of novel therapeutic agents, 1995-2017|
AD Zhang, J Puthumana, NS Downing, ND Shah, HM Krumholz, JS Ross
JAMA network open 3 (4), e203284-e203284, 2020
|Associations between deceased-donor urine MCP-1 and kidney transplant outcomes|
SG Mansour, J Puthumana, PP Reese, IE Hall, MD Doshi, FL Weng, ...
Kidney international reports 2 (4), 749-758, 2017
|Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents Over Three Decades, 1995-2017: Cross-Sectional Analysis|
AD Zhang, J Puthumana, NS Downing, ND Shah, H Krumholz, JS Ross
|Biomarkers of inflammation and repair in kidney disease progression|
J Puthumana, H Thiessen-Philbrook, L Xu, SG Coca, AX Garg, ...
The Journal of Clinical Investigation, 2020
|Speed, Evidence, and Safety Characteristics of Vaccine Approvals by the US Food and Drug Administration|
J Puthumana, AC Egilman, AD Zhang, JL Schwartz, JS Ross
JAMA Internal Medicine, 2020
|Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents over Three Decades, 1995-2017|
A Zhang, J Puthumana, N Shah, J Ross
2019 Annual Research Meeting, 2019
|Breakthrough Therapy Designation for New Drugs—Reply|
J Puthumana, JD Wallach, JS Ross
Jama 320 (19), 2042-2043, 2018
|Associations Between Deceased-Donor Urine MCP-1 and Kidney Transplant Outcomes.|
S Mansour, J Puthumana, P Reese, I Hall, M Doshi, F Weng, B Schroppel, ...
AMERICAN JOURNAL OF TRANSPLANTATION 16, 239-239, 2016
|YKL-40 Predicts Renal Recovery in Deceased-Donor Transplantation.|
J Puthumana, I Hall, P Reese, B Schroppel, F Weng, ...
AMERICAN JOURNAL OF TRANSPLANTATION 16, 298-298, 2016
|Sun protection practices among melanoma survivors.|
J Puthumana, L Ferrucci, S Mayne, D Lannin, A Chagpar
Cancer Research 73 (8 Supplement), 1365-1365, 2013
|Wiimote-iPhone Interface Applications for Neuromuscular Rehabilitation|
E Fu, R Narang, J Puthumana